Retractable Technologies, Inc.
http://www.retractable.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Retractable Technologies, Inc.
Cipla Lines Up A Slate Of US Launches For FY23
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
Big US Launch Promise For Cipla In FY23, Eyes On Peptide Filings
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
Keeping Track: US FDA Says Yes To AZ’s Farxiga In CKD And ADC’s Zynlonta, But No To Leo’s Tralokinumab, Chiesi’s Pegunigalsidase
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BD Has Paid Enough In False-Ad Suit, Appeals Court Says
Becton Dickinson won’t need to pay more to resolve a long-running false-advertising case, a federal appeals court has ruled in a split decision.
Company Information
- Industry
- Medical Devices